NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

NewAmsterdam Pharma Company N.V. (NAMS) Stock Analysis

NewAmsterdam Pharma Company N.V. (NAMS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NAMS

$25.40

−$0.45 (−1.74%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NAMS with… →

NAMS Key Statistics

As of Sep 4, 2026
Trading
Open
$25.65
Previous Close
$25.85
Day's Range
25.10–25.75
52-Week Range
23.05–42.21
Volume
697.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.09
Valuation
Market Cap
$2.97B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
416.99
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.16
Financials (FY)
Revenue (FY)
$22.50M−50.61%
Net Income (FY)
−$203.82M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
116.90M
1-Year Return
−1.01%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.07M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NAMS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−27.59%
2025+36.50%
2024+130.08%
2023+2.48%
2022+11.79%
2021 (partial year)−8.12%

As of September 4, 2026.

NAMS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$22.50M−$203.82M−905.7%
2024$45.56M−$241.60M−530.3%
2023$14.09M−$176.94M−1255.8%
2022$102.69M−$22.63M−22.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$22.50M—−$225.68M−$203.82M−905.7%
2024$45.56M—−$176.29M−$241.60M−530.3%
2023$14.09M—−$182.97M−$176.94M−1255.8%
2022$102.69M—−$3.56M−$22.63M−22.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NAMS Valuation vs Biotechnology Median

Median of 656 stocks
MetricNAMSBiotechnology medianvs median
P/S ratio416.9915.2627.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NewAmsterdam Pharma Company N.V. (NAMS) carries a market capitalisation of $2.97B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 100.

NAMS last closed at $25.40 on September 4, 2026. That is −$0.45 (−1.74%) against the previous close. The 52-week range on file runs from $23.05 to $42.21. The latest close sits 10.2% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $22.50M. That is −50.61% against the prior fiscal year, when revenue was $45.56M. The same year closed with a net loss of $203.82M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −2.16.

Across the 4 fiscal years on file, revenue moves from $102.69M in 2022 to $22.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 416.99 times revenue. On price-to-sales that is 27.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −1.01%. Measured over 5 years, that is +20.49% a year compounded. Beta against the wider market is reported at 0.09. Daily returns over the trailing 5 years annualize to a volatility of 61.17%.

Growth & Income

The record shows no dividend for NAMS.

The strongest complete calendar year on file is 2024 at +130.08%; the weakest is 2023 at +2.48%. Of the 4 complete calendar years on file, 4 finished higher. So far in 2026 the price is −27.59%.

Peer Comparison

NewAmsterdam Pharma Company N.V. (NAMS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NewAmsterdam Pharma Company N.V. NAMS $2.97B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. NewAmsterdam Pharma Company N.V. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Visit website →